Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Loans - Net Loans - Net Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Accured Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Accured Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Perspective Therapeutics (CATX) Receivables - Accured (2022 - 2025)

Perspective Therapeutics' Revenue - Other history spans 6 years, with the latest figure at $76000.0 for Q1 2026.

On a quarterly basis, Revenue - Other fell 77.78% to $76000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $618000.0, a 57.99% decrease, with the full-year FY2025 number at $884000.0, down 39.2% from a year prior.
Receivables - Accured hit $1.0 million in Q4 2025 for Perspective Therapeutics, up from $880000.0 in the prior quarter.
Over the last five years, Receivables - Accured for CATX hit a ceiling of $1.0 million in Q4 2025 and a floor of $109000.0 in Q4 2022.
Historically, Receivables - Accured has averaged $670666.7 across 3 years, with a median of $880000.0 in 2024.
Biggest five-year swings in Revenue - Other: skyrocketed 39.48% in 2024 and later crashed 81.62% in 2025.
Tracing CATX's Revenue - Other over 4 years: stood at $337000.0 in 2023, then tumbled by 30.56% to $234000.0 in 2024, then crashed by 81.62% to $43000.0 in 2025, then surged by 76.74% to $76000.0 in 2026.
Business Quant data shows Revenue - Other for CATX at $76000.0 in Q1 2026, $43000.0 in Q4 2025, and $209000.0 in Q3 2025.